Zanidatamab Shows Durable Activity and Pain Benefit in HER2‑Positive Metastatic Biliary Tract Cancer: Final HERIZON‑BTC‑01 Results
Final HERIZON‑BTC‑01 data show zanidatamab induces durable responses and a median overall survival of 15.5 months in previously treated HER2‑overexpressing metastatic biliary tract cancer, with greatest benefit in IHC 3+ tumors and manageable toxicity.